Conference paper

Ibandronate

Đurđica Babić-Naglić ; Clinic for Rheumatic Diseases and Rehabilitation, Clinical Hospital Centre Zagreb, Zagreb, Croatia
Simeon Grazio ; Clinic for Rheumatology, Physical Medicine and Rehabilitation, Clinical Hospital “Sestre milosrdnice”, Zagreb, Croatia

Abstract

Osteoporosis is chronic bone disorder that require persistent treatment. Bone fracture is the final outcome of OP and early diagnosis, active prevention, treatment and improvement of the patient adherence to treatment are needed. Ibandronate is a potent, nitrogen-containing bisphosphonate specifically developed for once-monthly oral and three-monthly administration with the same anti-resorptive efficacy. Ibandronate reduce vertebral fracture risk 50-60%, increase spine and hip BMD, 6% and 3%, significantly decrease biochemical markers of bone turnover without histomorphometric changes of bone. There is strong patient preference for once-monthly regimen and the favourable impact on therapeutic adherence. Intravenous ibandronate formulation is indicated for all patients who are unable to take oral medicine. Adverse events are infrequent, short duration and reversibile.

Keywords

adherence; ibandronate; osteoporosis

Hrčak ID:

125834

URI

https://hrcak.srce.hr/125834

Publication date:

20.10.2006.

Article data in other languages: croatian

Visits: 892 *